Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T18:51:54.198Z.
Calculation as of: 2026-10-06T18:51:54.198Z.
Quote observation: 2026-10-06T18:50:08.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 76fc2c3b696fe1037033af5d10d354cd3b8573abd6cfebee9ff2ae185940ee40
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$2.40B
PS Ratio
0.97
TTM Avg
0.83
3Y Avg
0.79
5Y Avg
0.74
Market Cap
$2.40B
PS Ratio
43.76
TTM Avg
33.48
3Y Avg
36.04
5Y Avg
67.42
Market Cap
$2.45B
PS Ratio
2.95
TTM Avg
3.78
3Y Avg
3.16
5Y Avg
3.11
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Disc Medicine, Inc. (IRON) | $2.41B | N/A | N/A | N/A | N/A |
| Clover Health Investments, Corp. (CLOV)vs › | $2.40B | 0.97 | 0.83 | 0.79 | 0.74 |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.40B | 43.76 | 33.48 | 36.04 | 67.42 |
| ADMA Biologics, Inc. (ADMA)vs › | $2.36B | 4.61 | 6.19 | 8.09 | 6.53 |
| Supernus Pharmaceuticals, Inc. (SUPN)vs › | $2.45B | 2.95 | 3.78 | 3.16 | 3.11 |
| Nurix Therapeutics, Inc. (NRIX)vs › | $2.35B | 63.92 | 33.46 | 21.55 | 20.85 |
| Liquidia Corporation (LQDA)vs › | $2.33B | 5.17 | 36.08 | 55.20 | 43.60 |
| UFP Technologies, Inc. (UFPT)vs › | $2.33B | 3.69 | 3.05 | 3.78 | 3.40 |
| Alamar Biosciences, Inc. (ALMR)vs › | $2.30B | N/A | N/A | N/A | N/A |
| NewAmsterdam Pharma Company N.V. (NAMS)vs › | $2.52B | 354.41 | 189.81 | 133.81 | 91.05 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-06 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-31 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-13 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-07-30 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
